General
Preferred name
aficamten
Synonyms
CK-274 ()
CK-3773274 ()
CK 3773274 ()
Aficamten (CK-274) ()
P&D ID
PD154870
CAS
2364554-48-1
Tags
available
drug candidate
Drug Status
investigational
Max Phase
3.0
Drug indication
hypertrophic cardiomyopathy
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 ¦ÌM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM)[1].
PRICE 190
DESCRIPTION Aficamten (CK-3773274) is an orally administered cardiac myosin inhibitor that was developed by Cytokinetics as a potential treatment for hypertrophic cardiomyopathies . It was designed to reduce the hypercontractility of cardiac sarcomeres that is thought to drive hypertrophy and fibrosis in heart muscle, by binding directly to a distinct and selective allosteric binding site on cardiac myosin. (GtoPdb)
DESCRIPTION Aficamten is a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
7
Cayman Chemical Bioactives
36304
ChEMBL Drugs
CHEMBL4847050
DrugBank
DB18490
Guide to Pharmacology
11524
MedChem Express Bioactive Compound Library
HY-139465
Selleckchem Bioactive Compound Library
aficamten-ck-274
TargetMol Bioactive Compound Library
T9258
External IDs
13
Properties
(calculated by RDKit )
Molecular Weight
337.15
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
3
cLogP
2.45
TPSA
85.84
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Myosin
Cardiac Myosin
Pathway
cytoskeleton
Source data